Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma

Ayhan Ulusakarya,Nahla Teyar,Abdoulaye Karaboué,Mazen Haydar,Sarra Krimi,Pamela Biondani,Yusuf Gumus,Amale Chebib,Wathek Almohamad,Jean-François Morère

Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma

2019

Ayhan Ulusakarya
Nahla Teyar
Abdoulaye Karaboué
Mazen Haydar
Sarra Krimi
Pamela Biondani
Yusuf Gumus
Amale Chebib
Wathek Almohamad
Jean-François Morère

AbstractFOLFIRINOX is one of the most effective reference regimens in the 1st line treatment of locally advanced (LA) and metastatic pancreatic cancer (mPC), despite its high toxicity. We evaluated our real-life experience with “patient-tailored intent to treat FOLFIRINOX” in patients with LA or mPC

Keywords:

Physical therapy
Diabetes mellitus
Medicine
Oncology
Internal medicine
FOLFIRINOX
Adenocarcinoma
first line treatment
in patient
Intention-to-treat analysis
Metastatic pancreatic cancer
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations